Neuropathix (NPTX) 10-K 30 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 30, 2021	Jun. 30, 2020
Document And Entity Information
Entity Registrant Name	NEUROPATHIX, INC.
Entity Central Index Key	0001615999
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Is Entity Emerging Growth?	true
Is Entity Small Business?	true
Entity Extended Transition Period?	false
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Incorporation, State or Country Code	DE
Entity File Number	000-55657
Entity Interactive Data Current	Yes
Entity Public Float			$ 15,478,542
Entity Common Stock, Shares Outstanding		87,286,137
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 21,874	$ 121,455
Prepaid expenses	161,000	9,000
Other receivables	400	400
Total Current Assets	183,274	130,855
NON-CURRENT ASSETS:
Property and equipment, net	59,266	75,401
Security deposits	17,121	17,121
Total Non-Current Assets	76,387	92,522
TOTAL ASSETS	259,661	223,377
CURRENT LIABILITIES:
Accounts payable and accrued expenses	721,308	389,195
Payroll and related liabilities	379,241	243,208
Loan payable	950,000	620,000
Loan payable - related party	42,092	42,092
Convertible notes payable, net of $198,747 debt discount	198,127	0
Capital lease obligations	8,471	7,533
Patent purchase liability	53,135	0
Due to related party, net	55,258	25,349
Derivative liabilities	138,046	0
Total Current Liabilities	2,545,678	1,327,377
LONG TERM LIABILITIES:
Convertible notes payable - long term	376,373	378,839
Convertible notes payable - long term, net of $80,000 debt discount - related party	70,000	0
Capital lease obligation - long term portion	19,293	27,764
Patent purchase liability - long term	264,826	0
Derivative liabilities - long term	178,143	183,451
Total Long Term Liabilities	908,635	590,054
TOTAL LIABILITIES	3,454,313	1,917,431
Commitments and contingencies (Note 14)	0	0
STOCKHOLDERS' DEFICIT:
Common stock, $0.0001 par value, 200,000,000 authorized, 77,670,908 and 74,225,141 issued and outstanding, respectively	7,767	7,422
Additional paid-in capital	9,830,944	6,794,612
Accumulated deficit	(13,033,363)	(8,496,088)
TOTAL STOCKHOLDERS' DEFICIT	(3,194,652)	(1,694,054)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	259,661	223,377
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized	0	0
Series B Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Debt discount current	$ 205,873
Debt discount noncurrent	$ 80,000
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	77,670,908	74,225,141
Common Stock, Shares, Outstanding	77,670,908	74,225,141
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized	75	75
Preferred Stock, Shares Issued	75	75
Preferred Stock, Shares Outstanding	75	75
Liquidation preference	$ 75,000	$ 75,000
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized	75	75
Preferred Stock, Shares Issued	75	75
Preferred Stock, Shares Outstanding	75	75
Liquidation preference	$ 75,000	$ 75,000

Consolidated Statments of Opera

Consolidated Statments of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
NET REVENUES:
Grant revenue	$ 0	$ 126,027
TOTAL NET REVENUES	0	126,027
OPERATING EXPENSES:
Research and development	1,095,405	554,701
General and administrative	3,378,323	1,900,443
TOTAL OPERATING EXPENSES	4,473,728	2,455,144
LOSS FROM OPERATIONS	(4,473,728)	(2,329,117)
OTHER INCOME (EXPENSE)
Interest expense, net	(924,227)	(146,909)
Other (expense) income, net	108,185	0
Net gains and losses recognized on marketable security	0	(942,982)
Impairment on investment	0	(27,490)
Change in fair value of derivative liabilities	752,495	(4,367)
TOTAL OTHER INCOME (EXPENSE)	(63,547)	(1,121,748)
NET LOSS BEFORE INCOME TAX	(4,537,275)	(3,450,865)
Income tax expense	0	0
NET LOSS	(4,537,275)	(3,450,865)
Net loss attributable to noncontrolling interests	0	(6,828)
Net loss attributable to Neuropathix, Inc.	$ (4,537,275)	$ (3,444,037)
Loss attributable to Neuropathix, Inc. per common share - basic and diluted	$ (0.06)	$ (0.05)
Weighted average common shares outstanding - basic and diluted	74,623,944	71,228,125

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Series A Preferred Stock	Series B Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Noncontrolling Interest	Total
Beginning balance, Shares at Dec. 31, 2018	75	75	69,854,141
Beginning balance, Amount at Dec. 31, 2018			$ 6,985	$ 6,381,755	$ (5,052,051)	$ (5,756)	$ 1,330,933
Issuance of common stock for conversion of notes payable and accrued interest, Shares			1,500,000
Issuance of common stock for conversion of notes payable and accrued interest, Amount			$ 150	149,850			150,000
Issuance of stock options for services				5,878			5,878
Issuance of common stock for services, Shares			1,750,000
Issuance of common stock for services, Amount			$ 175	174,825			175,000
Issuance of common stock to board members for services, Shares			950,000
Issuance of common stock to board members for services, Amount			$ 95	94,905			95,000
Issuance of common stock for remaining share of non-controlling interest, Shares			171,000
Issuance of common stock for remaining share of non-controlling interest, Amount			$ 17	(12,601)		12,584
Reduction of derivative liability
Net loss					(3,444,037)	(6,828)	(3,450,865)
Ending balance, Shares at Dec. 31, 2019	75	75	74,225,141
Ending balance, Amount at Dec. 31, 2019			$ 7,422	6,794,612	(8,496,088)		(1,694,054)
Stock based compensation				1,722,599			1,722,599
Issuance of common stock for acquisition of intellectual property, Shares			1,025,000
Issuance of common stock for acquisition of intellectual property, Amount			$ 103	283,148			283,251
Issuance of common stock for conversion of notes payable and accrued interest, Shares			570,767
Issuance of common stock for conversion of notes payable and accrued interest, Amount			$ 57	119,675			119,732
Issuance of common stock for services, Shares			1,850,000
Issuance of common stock for services, Amount			$ 185	844,523			844,708
Reduction of derivative liability				66,387			66,387
Net loss					(4,537,275)		(4,537,275)
Ending balance, Shares at Dec. 31, 2020	75	75	77,670,908
Ending balance, Amount at Dec. 31, 2020			$ 7,767	$ 9,830,944	$ (13,033,363)		$ (3,194,652)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,537,275)	$ (3,450,865)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	16,135	5,509
Amortization of debt discount	376,661	2,466
Stock based compensation	1,722,600	275,878
Issuance of common stock for services	594,708	0
Issuance of common stock and debt for acquisition of intellectual property	601,211	0
Non-cash interest expense	432,170	79,084
Change in fair value of derivative liabilities	(752,495)	4,367
Net gains and losses recognized on marketable security	0	942,982
Impairment on investment	0	27,490
Changes in operating assets and liabilities:
Prepaid expenses	98,000	(9,000)
Other receivables	0	99,291
Accounts payable and accrued expenses	338,145	131,572
Payroll and related liabilities	136,033	(2,859)
Due to related party, net	29,909	0
NET CASH USED IN OPERATING ACTIVITIES	(944,198)	(1,894,085)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of marketable securities	0	1,636,658
Purchase of equipment	0	(41,950)
Purchase of other asset	0	(27,490)
NET CASH PROVIDED BY INVESTING ACTIVITIES	0	1,567,218
CASH FLOWS FROM FINANCING ACTIVITIES:
Due from related party, net	0	16,334
Due to related party, net	0	25,349
Principal payments toward capital lease obligations	(7,533)	(589)
Proceeds from loan payable	330,000	0
Proceeds from loan payable - related party	0	97
Proceeds from convertible notes payable, net of OID	372,150	0
Proceeds from convertible notes payable - related party	150,000	100,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	844,617	141,191
Net decrease in cash	(99,581)	(185,676)
Cash and cash equivalents, beginning of year	121,455	307,131
Cash and cash equivalents, end of year	21,874	121,455
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	16,262	0
Cash paid for taxes	0	0
NON-CASH ACTIVITIES:
Issuance of common stock for conversion of notes payable and accrued interest	117,032	150,000
Issuance of common stock for prepaid expenses	250,000	0
Issuance of common stock for remaining share of non-controlling interest	0	12,584
Property and equipment financed through capital leases	0	35,886
Debt discount upon the issuance of convertible note payable	372,150	0
Debt discount upon the issuance of convertible note payable - related party	150,000	100,000
Reduction of derivative liability	$ 66,387

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	Note 1 – Organization and Nature of Operations Neuropathix, Inc. (the “Company”) was incorporated under the laws of the state of Delaware on March 25, 2013 under the name TYG Solutions Corp. The Company consummated a share exchange transaction on July 25, 2018 with Kannalife Sciences, Inc. (“Kannalife”), a privately held Delaware corporation formed in 2010, the accounting acquirer. Upon completion of the share exchange transaction, Kannalife was treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of Kannalife the surviving entity and accounting acquirer. All references that refer to (the “Company” or “we” or “us” or “our”) are Kannalife, unless otherwise differentiated. Kannalife is a phytomedical/pharmaceutical company that specializes in the research and development of synthetic molecules and therapeutic products derived from botanical sources, including the cannabis taxa. On November 9, 2018, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State that changed its name to Kannalife, Inc. Name Change – Neuropathix, Inc. On November 4, 2020, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State that changed its name to Neuropathix, Inc. The Company concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change from “KLFE” to “NPTX.” The Company’s name change and ticker symbol change was reviewed and processed by FINRA and went effective November 6, 2020.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies The significant accounting policies used in the preparation of the consolidated financial statements are as follows: Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Kannalife. All significant consolidated transactions and balances have been eliminated in consolidation. Noncontrolling Interests The Company accounts for its less than 100% interests in Kannalife in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of Kannalife’s net loss attributable to noncontrolling interests in the consolidated statement of operations. On August 30, 2019, the Company issued 171,000 shares of common stock at a price of $0.07 per share to acquire the remaining non-controlling interest in Kannalife Sciences, Inc., bringing our ownership interest from 99.7% to 100%. Significant Risks and Uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. In December 2019, a novel strain of coronavirus, commonly known as COVID-19, surfaced. The spread of COVID-19 around the world in 2020 has caused significant volatility in U.S. and international markets. The Company’s operations as of December 31, 2020 have not been significantly affected, but may be affected in the future, by the ongoing outbreak of COVID-19 which was declared a pandemic by the World Health Organization. The ultimate disruption which may be caused by the outbreak is uncertain; however, it may result in a material adverse impact on the Company’s financial position, operations and cash flows. Possible areas that may be affected include, but are not limited to, disruption to the Company’s labor workforce, unavailability of products and supplies used in operations, and the decline in value of assets held by the Company. Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Company’s stock, stock-based compensation, valuation of derivative liabilities and valuation allowance relating to the Company’s deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made. Cash and Cash Equivalents Our cash and cash equivalents include short-term, highly liquid investments with original maturities of three months or less when purchased. At times throughout the year, the Company may maintain bank balances that could exceed Federal Deposit Insurance Corporation insured limits. The Company maintains its cash deposit accounts with high credit quality financial institutions, and therefore believes that its loss exposure is minimal. Accounts Receivable Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers’ accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. As of December 31, 2020 and 2019, the Company had no allowance for doubtful account. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense when incurred, while renewals and betterments that materially extend the life of an asset are capitalized. When assets are sold, retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheets and any resulting gain or loss is reflected in the statements of operations and members’ deficit in the period realized. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are as follows: Furniture and equipment 5 years Joint Venture On June 18, 2019, the Company, along with MJNA, which is a significant shareholder, and AXIM Biotechnologies, Inc., whose president is affiliated with a shareholder, entered into a joint venture agreement with an industrial hemp production farm for the supply of certain industrial hemp CBD crops. The purpose of the joint venture is to share in the harvested yield of the hemp production which the Company hopes to result in a steady supply of industrial hemp CBD for research and development purposes. The Company accounts for its participation in the joint venture under the equity method of accounting. The Company has no control or influence over the joint venture and for the year ending December 31, 2019 the Company recorded a loss in investment in the amount of $27,490. As of December 31, 2020, the Company is no longer part of this joint venture. Revenue Recognition The FASB issued Accounting Standards Update (“ASU”) No. 2014-09, codified as ASC 606: Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. Revenue consists of research funding from the Company’s National Institute of Health (“NIH”) Grant. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met. For the year ended December 31, 2020, the company recognized $0 in grant revenue. Equity Investments Effective January 1, 2018, with the adoption of ASU 2016-01, our accounting treatment for equity investments differs for those with and without readily determinable fair values. Equity investments with readily determinable fair values are recorded at fair value with changes in fair value recorded in “Unrealized Gain/Loss On Investments.” For equity investments without readily determinable fair values we have elected the “measurement alternative,” and therefore carry these investments at cost, less impairment (if any), plus or minus changes in observable prices. On a quarterly basis, we review our equity investments without readily determinable fair values for impairment. We consider a number of qualitative factors such as whether there is a significant deterioration in earnings performance, credit rating, asset quality, or business prospects of the investee in determining if impairment exists. If the investment is considered impaired, an impairment loss equal to the amount by which the carrying value exceeds its fair value is recorded through a charge to earnings. The impairment loss may be reversed in a subsequent period if there are observable transactions for the identical or similar investment of the same issuer at a higher amount than the carrying amount that was established when the impairment was recognized. Impairment as well as upward or downward adjustments resulting from observable price changes in orderly transactions for identical or similar investments are included in “Income - other.” Realized gains or losses resulting from the sale of equity investments are calculated using the specific identification method and are included in “Net gains and losses recognized on marketable security". Income Taxes The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes Preferred Stock The Company applies the guidance enumerated in FASB ASC Topic 480, Distinguishing Liabilities from Equity Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC Topic 815, Derivatives and Hedging Activities Applicable U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments) as follows. The Company records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares. Stock Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provision of FASB ASC 718, Compensation – Stock Compensation The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505, Equity–based Payments to Non-Employees . Net Loss per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 17,174,152 and 4,029,433 for the years ended December 31, 2020 and 2019, respectively. Research and Development In accordance with FASB ASC 730, Research and Development Recently Issued Authoritative Guidance In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation is not needed until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s consolidated financial statements.

Going Concern and Management's

Going Concern and Management's Liquidity Plans	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Liquidity Plans	Note 3 – Going Concern and Management’s Liquidity Plans The Company’s consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in our accompanying consolidated financial statements, the Company has had a net loss from operations of $4,473,728 and $2,329,117 for the years ended December 31, 2020 and 2019, respectively. The net cash used in operations were $(944,198) and $(1,894,085) for the years ended December 31, 2020 and 2019, respectively. Additionally, the Company had an accumulated deficit of $13,033,363 at December 31, 2020 and has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. These factors raise substantial doubt about its ability to continue as a going concern. In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management plans to raise additional capital through the sale of convertible debt securities offering. However, there are no assurances that such additional funding will be achieved or that management’s plans will be successful. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements The Company follows FASB ASC 820, Fair Value Measurements and Disclosures Level 1 - Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 - Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 - Pricing inputs that are generally unobservable inputs and not corroborated by market data. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying amounts reported in the Company’s consolidated financial statements for cash, accounts payable and accrued expenses approximate their fair value because of the immediate or short-term nature of these financial instruments. Transactions involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm's-length transactions unless such representations can be substantiated. The following table presents liabilities that are measured and recognized at fair value as of December 31, 2020 and 2019, on a recurring basis: December 31, 2020 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities — — 316,189 $ 316,189 December 31, 2019 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities — — 183,451 $ 183,451

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at December 31, 2020 and 2019 consisted of the following: December 31, 2020 December 31, 2019 Accounts payable and accrued expenses $ 538,527 $ 309,231 Accrued interest 182,781 79,964 Totals $ 721,308 $ 389,195

Payroll and Related Liabilities

Payroll and Related Liabilities	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Payroll and Related Liabilities	NOTE 6 – PAYROLL AND RELATED LIABILITIES Payroll and related liabilities at December 31, 2020 and 2019 consisted of the following: December 31, 2020 December 31, 2019 Payroll $ 149,704 $ — Payroll taxes 229,537 243,208 Totals $ 379,241 $ 243,208 As of the year ended December 31, 2020, the Company has accrued payroll and payroll taxes in connection with salaries paid and accrued to four officers of the Company, which includes $130,000 accrued for the CEO, and $12,500 accrued for executive management.

Loan Payable

Loan Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Loan Payable	NOTE 7 – LOAN PAYABLE December 31, 2020 December 31, 2019 Loan payable at 8%, matures 12/31/2020 * {a} $ 850,000 $ 620,000 Loan payable at 0%, matures 6/11/2021 * 100,000 — Total 950,000 620,000 {a} – The maturity date of the loan has been extended to December 31, 2021. * - unsecured note Total interest expense on notes payable, amounted to $54,444 and $48,921 for the years ended December 31, 2020 and 2019, respectively. Accrued interest related to these notes was $127,825 and $73,381 as of December 31, 2020 and 2019, respectively.

Loan Payable - Related Party

Loan Payable - Related Party	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Loan Payable - Related Party	NOTE 8 – LOAN PAYABLE – RELATED PARTY Prior to the share exchange agreement, the Company borrowed $25,822 and issued a promissory note with a maturity date of March 31, 2020 which was later extended to March 31, 2021. Additionally, the note holder advanced the Company $16,270 for working capital, for a total of $42,092 – also see Note 16. The loans represent working capital advances from shareholders, bear interest at 0.5%, and grant a security interest in the Company’s assets as collateral. In March 2018, this note was amended, and the original note holder assigned the note to Kettner Investments, LLC, a significant shareholder. The note is now non-interest bearing. Accrued interest related to this note is $226 as of December 31, 2020 and 2019, respectively.

Capital Lease Obligations

Capital Lease Obligations	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Capital Lease Obligations	NOTE 9 – CAPITAL LEASE OBLIGATIONS In September 2019, the Company entered into a lease agreement with Thermo Fisher Scientific to acquire equipment with 48 monthly payments of $941, payable through September 1, 2023, with an effective interest rate of 12% per annum. The outstanding balance of this capital lease was $27,764, secured by equipment with carrying value of $46,131, as of December 31, 2020.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Convertible Notes Payable	NOTE 10 – CONVERTIBLE NOTES PAYABLE Prior to the Share Exchange, the Company issued a convertible note to an investor, face value of $500,000, in exchange for $500,000 in cash. The note is unsecured, bears interest at the rate of 3% per annum and matures on February 16, 2030. The note is convertible into common stock of the Company at $0.10 per share at any time at the option of the holder, subject to a 4.9% blocking provision which prohibits the holder from converting into common stock of the Company if such conversion results in the holder owning greater than 4.9% of the outstanding common stock of the Company after giving effect to such conversion. On September 26, 2019, the Company issued 1,500,000 shares of common stock for the conversion of $123,627 convertible notes payable and $26,373 of related accrued interest. The outstanding balance on this convertible note after the conversion was $376,373. In December 2019, the Company entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell to the investor a $100,000 convertible note bearing interest at 8% per annum (the “Note”). The Note matures two years from the date of issuance. The Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of 75% of the average closing price of the Company’s common stock on the fifteen days prior to conversion. The Company may not prepay this Note within the first six months. If, after the first six months until the maturity of the Note the Company: (a) elects to repay the Note, it must do so at a premium of one hundred and twenty five percent (125%) of the face amount of the Note, together with all unpaid and accrued interest to the date of repayment. (b) elects to involuntarily exercise conversion of this Note to the Holder, the Company must provide written notice to the Holder along with an executed copy of the Company’s Notice of Conversion, specifying that the Note shall be converted into shares of the Company’s Common Stock based upon at an effective conversion price of 75% of the average closing price of the Company’s common stock on the fifteen days prior to conversion. The embedded conversion feature of this Note was deemed to require bifurcation and liability classification, at fair value. Pursuant to the Securities Purchase Agreement, the Company also sold warrants to the investors to purchase up to an aggregate of 100,000 shares of common stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 13) resulting in full discount of the Note. On March 12, 2020, the Company entered into securities purchase agreements with two different accredited investors (each an “Investor”, and together the “Investors”) pursuant to which each Investor purchased an 8% unsecured convertible promissory note (each a “8% Note”, and together the “8% Notes”) from the Company. The terms and conditions of each of the 8% Notes are substantially the same. Each 8% Note has a principal amount of $105,000 less a $5,000 original issue discount for a purchase price of $100,000, with a maturity date of March 12, 2021. All principal amounts and the interest thereon are convertible into shares of the Company’s common stock at the option of each Investor, after six (6) months from the date of the 8% Notes. These 8% Notes have a variable conversion price and the Company recorded embedded derivative liabilities. The Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of the lesser of (i) $0.75 or (ii) 68% multiplied by the average of the two lowest trading closing prices of the Company’s common stock on the fifteen days before the issue date of this note or (ii) 68% multiplied by the average of the two lowest trading closing prices of the Company’s common stock on the fifteen days prior to conversion. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the 8% Note (see Note 13) resulting in full discount of the 8% Note. During the year ended December 31, 2020, the Company issued 570,767 shares of common stock for the conversion of $111,000 convertible notes payable and $6,032 of related accrued interest. The outstanding balance on these convertible notes after the conversion was $99,000. On June 8, 2020, the Company entered into a securities purchase agreement, dated as of June 2, 2020 (the “Purchase Agreement”), with an accredited investor pursuant to which the investor purchased a 12% unsecured convertible promissory note (the “12% Note”) from the Company. The 12% Note has a principal amount of $165,000 less a $9,000 original issue discount (“OID”) for a purchase price of $156,000, of which $52,000 was paid on June 8, 2020 less $3,100 in transaction fees (the “First Tranche”). The 12% Note matures 12 months from the effective date of each tranche. All principal amounts and the interest thereon are convertible into shares of the Company’s common stock at the option of the Investor, after six (6) months from the date of the 12% Note. All closings occurred following the satisfaction of customary closing conditions. The 12% Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of the lesser of (i) 68% multiplied by the lowest Trading Price (representing a discount rate of 32%) during the previous fifteen (15) trading day period ending on the latest complete trading day prior to the date of the 12% Note or (ii) the Variable Conversion Price. In connection with the Purchase Agreement and the 12% Note, the Company issued a common stock purchase warrant to purchase 36,666 shares of the Company’s common stock at $0.75 per share (the “Warrant”) which may be exercised by cashless exercise, exercisable for a period of three years. The 12% Note has a variable conversion price and the Company recorded embedded derivative liabilities. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the 12% Note (see Note 13) resulting in full discount of the 12% Note. On June 23, 2020, the Company entered into a securities purchase agreement, dated as of June 19, 2020, with an accredited investor pursuant to which the investor purchased a 12% convertible promissory note in the principal amount of $150,000, less $20,750 in transaction-related, broker, legal and due diligence expenses. The note matures on June 19, 2021. Principal payments on the note shall be made in six (6) installments, each in the amount of $25,000, starting on December 19, 2020, and continuing thereafter each thirty (30) days for five (5) months. Notwithstanding the foregoing, the final payment of principal and accrued and unpaid interest shall be due on the June 19, 2021. The investor is entitled to, at its option, convert all or any amount of the principal amount and any accrued but unpaid interest of the note into shares of the Company’s common stock, at any time upon an event of default, at a conversion price for each share of common stock equal to the lesser of (i) the lowest trading price during the previous five (5) trading day period ending on the latest complete trading day prior to the date of the note, or (ii) the Variable Conversion Price, subject to certain equitable adjustments. Furthermore, in connection with the securities purchase agreement and the note, the Company issued two common stock purchase warrants each to purchase 115,385 shares of the Company’s common stock at $1.30 per share which may be exercised by cashless exercise, exercisable for a period of five years. One of the warrants only becomes exercisable upon default of the note. During the second half of 2020, the anti-dilution clause was triggered, and the exercise price was reset to $0.15 resulting in the number of warrants to be increased to 1,002,677. The note has a variable conversion price and the Company recorded embedded derivative liabilities. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the note (see Note 13) resulting in full discount of the note. Total interest expense on convertible notes payable, inclusive of amortization of debt discount of $306,662 and $2,466, amounted to $349,889 and $16,739 for the years ended December 31, 2020 and 2019, respectively. Total accrued interest on convertible notes payable, for the years ended December 31, 2020 and 2019, was $39,993 and $2,797, respectively.

Convertible Notes Payable - Rel

Convertible Notes Payable - Related Party	12 Months Ended
	Dec. 31, 2020
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract]
Convertible Notes Payable - Related Party	NOTE 11 – CONVERTIBLE NOTES PAYABLE – RELATED PARTY In January 2020, the Company sold an additional $100,000, to Kettner Investments, LLC, a significant shareholder, under the Note and sold warrants to purchase up to an aggregate of 100,000 shares of common stock under the Securities Purchase Agreement. The loan is due by December 22, 2021 and accrues interest at a rate of 8% per annum. The Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of 75% of the average closing price of the Company’s common stock on the fifteen days prior to conversion. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 13) resulting in full discount of the Note. In February 2020, the Company sold an additional $50,000, to the CEO of MJNA, a significant shareholder, under the Note and sold warrants to purchase up to an aggregate of 50,000 shares of common stock under the Securities Purchase Agreement. The loan is due by February 2, 2022 and accrues interest at a rate of 8% per annum. The Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of 75% of the average closing price of the Company’s common stock on the fifteen days prior to conversion. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 13) resulting in full discount of the Note. Total interest expense on convertible notes payable – related party, inclusive of amortization of debt discount of $70,000 and $0, amounted to $81,178 and $0 for the years ended December 31, 2020 and 2019, respectively. Total accrued interest on convertible notes payable – related party, for the years ended December 31, 2020 and 2019, was $11,178 and $0, respectively. The following is a schedule by year of future debt payments at December 31, 2020. Year Ending December 31, Loan payable Loan payable - related party Convertible notes payable Convertible notes payable - related party Total 2021 $ 950,000 $ 42,092 $ 40,400 $ 100,000 $ 1,496,092 2022 — — — $ 50,000 $ 50,000 2023 — — — — — 2024 — — — — — 2025 — — — — — Thereafter — — $ 376,373 — $ 376,373 Total $ 950,000 $ 42,092 $ 780,373 $ 150,000 $ 1,922,465

Patent Purchase Liability

Patent Purchase Liability	12 Months Ended
	Dec. 31, 2020
Notes To Financial Statements Abstract
PATENT PURCHASE LIABILITY	NOTE 12 – PATENT PURCHASE LIABILITY On December 17, 2020, the Company entered into an Intellectual Property Rights Purchase and Transfer Agreement (the “IP Purchase Agreement”) by and between Advanced Neural Dynamics (“AND”), Fox Chase, Dr. Douglas Brenneman (“Brenneman”) and the Company to acquire the IP Rights and concurrently entered into a Pharmaceutical Royalty Agreement with AND and Fox Chase. Pursuant to the IP Purchase Agreement, the Company acquired the IP Assets for a $570,000 aggregate purchase price payable in restricted common stock of the Company to Fox Chase, Brenneman and AND, payable as follows: • 1,000,000 shares of restricted common stock of the Company were issued to Fox Chase at a price per share of $0.27 for an aggregate of $270,000; and • $300,000 in common stock will be issued to AND/Brenneman in five annual installments which shall be calculated as $60,000 divided by the average ten (10) day closing price prior to each installment date with the initial installment date occurring on January 5, 2021; provided, however, that for the initial installment issuance price only, the price per share shall not be below $0.30 or above $0.60 per share. In addition, AND/Brenneman shall receive cash payments of $15,000 annually, payable in quarterly installments to offset against tax payments, netted out against actual tax costs incurred. In the event such payments are not made, there will be a 10% penalty assessed on said late tax offset payment. The liabilities from the IP purchase agreement are recognized at the commencement date based on the present value of remaining payments over the payment term using the Company’s secured incremental borrowing rates or implicit rates, when readily determinable. The Company’s IP purchase agreement does not provide an implicit rate that can readily be determined. Therefore, the Company uses an 8% discount rate based on our incremental borrowing rate, which is determined using the average interest rate of our long-term debt as of December 17, 2020. For the year ended December 31, 2020, the Company expensed $587,962 related to the patent purchase which was included in research and development expenses on the accompanying consolidated statements of operations. Maturity of Patent Purchase Liability 2021 $ 75,000 2022 75,000 2023 75,000 2024 75,000 2025 75,000 Total undiscounted payments $ 375,000 Less: imputed interest 57,038 Present value of patent purchase liabilities $ 317,962

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2020
Notes To Financial Statements Abstract
Derivative Liabilities	NOTE 13 – DERIVATIVE LIABILITIES The Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. In addition, the Company issued warrants with variable conversion provisions. The conversion terms of the convertible notes and warrants are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date. Based on the various convertible notes described in Note 10 and 11, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows for the year ended December 31, 2020: Derivative Liability - Convertible Notes Derivative Liability - Warrants Total Balance as of December 31, 2019 $ 61,430 $ 122,021 $ 183,451 Additions during the period 597,841 353,779 951,620 Change in fair value (439,744 ) (312,751 ) (752,495 ) Change due to exercise / redemptions (66,387 ) — (66,387 ) Balance as of December 31, 2020 $ 153,140 $ 163,049 $ 316,189 The fair value of the derivative liability – convertible notes is estimated using a Monte Carlo pricing model with the following assumptions: Market value of common stock $0.14 – 0.58 Expected volatility 87.9% - 112.7% Expected term (in years) 0.19 – 2.00 Risk-free interest rate 0.06% - 1.55% The fair value of the derivative liability – warrants is estimated using a Monte Carlo pricing model with the following assumptions: Market value of common stock $0.58 - 1.80 Expected volatility 0.98% - 160.1% Expected term (in years) 1.98 - 5.00 Risk-free interest rate 0.18% - 1.57%

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 14 – COMMITMENTS AND CONTINGENCIES Legal Proceedings From time to time the Company may get involved in legal proceedings arising in the ordinary course of business. Other than as set forth in “Legal Proceedings” in Part II below, the Company believes there is no litigation pending that could have, individually or in the aggregate, a material adverse effect on its results of operations or financial condition. Occupancy Leases On April 1, 2014, the Company entered into a one year lease arrangement for office space, with the option to renew the lease annually. The lease has been renewed through April 2021. The monthly rent payment is $5,600 and the security deposit is $15,000. On September 15, 2015, we entered into a one year lease arrangement for additional office space, the lease has been renewed is currently scheduled to expire on September 30, 2021. The monthly rent payment is $359, and we provided a security deposit of $183. On July 1, 2018, we entered into a one year lease arrangement for additional office space, with the option to renew the lease annually. On September 1, 2018, we subleased this office space to a third party. The subleasee will pay 50% of the rent until expiration of lease on June 30, 2021. The monthly rent payment is $2,723, and we provided a security deposit of $2,121. Royalties On December 17, 2020, the Company entered into an Intellectual Property Rights Purchase and Transfer Agreement by and between Advanced Neural Dynamics (“AND”), Fox Chase, Dr. Douglas Brenneman (“Brenneman”) and the Company to acquire the IP Rights and concurrently entered into a Pharmaceutical Royalty Agreement (the “Royalty Agreement”) with AND and Fox Chase. Pursuant to the Royalty Agreement, the following royalties and license fees are payable to Fox Chase and AND as well: • 1% royalties on net sales up to $500,000 per year per participant (for an aggregate maximum of 2% and up to $1,000,000); • 1% upfront sublicense fees per participant; and • 1% reversion rights to each participant (for 2% aggregate), which rights include future milestone payments.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Stockholders' Equity	NOTE 15 – STOCKHOLDERS’ DEFICIT Series A Preferred Stock Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series A Preferred Stock. Each share of the Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company’s board of directors and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share. Series B Preferred Stock Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series B Preferred Stock. Each share of the Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Company’s board of directors and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders of Series B Preferred Stock are entitled to cast 1,000 votes per share. Common Stock The Company is authorized to issue 200,000,000 shares of common stock, par value of $0.0001 per share. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders. Equity Purchase Agreement with Cross & Company On September 18, 2020, the Company entered into a Equity Purchase Agreement with Cross and Company. We have the right to “put,” or sell, up to 8,108,108 shares of our common stock to Cross. Unless terminated earlier, Cross’s purchase commitment will automatically terminate on the earlier of the date on which Cross shall have purchased shares pursuant to the Equity Purchase Agreement for an aggregate purchase price of $6,000,000 or September 18, 2023. In August 2019, the Company issued 950,000 shares of common stock at the price of $0.10 per share to board members for general compensation for services rendered. In August 2019, the Company issued 500,000 shares of common stock at the price of $0.10 per share to an investor relations consultant for services rendered. In August 2019, the Company issued 150,000 shares of common stock at the price of $0.10 per share to a product development consultant for services rendered. In August 2019, the Company issued 400,000 shares of common stock at the price of $0.10 per share to a marketing consultant for services rendered. In August 2019, the Company issued 700,000 shares of common stock at the price of $0.10 per share to consultants for general compensation for services rendered. This compensation is included in research and development on the condensed consolidated statement of operations. On August 30, 2019, the Company issued 171,000 shares of common stock at a price of $0.07 per share to acquire the remaining non-controlling interest in Kannalife Sciences, Inc., bringing our ownership interest from 99.7% to 100%. On September 26, 2019, the Company issued 1,500,000 shares of common stock at a price of $0.10 per share for the conversion of $123,627 convertible notes payable and $26,373 of related accrued interest. On April 28, 2020, the Company executed an intellectual property rights purchase and transfer agreement whereby this agreement grants certain IP to the Company. In connection with the execution of this agreement, the Company issued 25,000 shares of the Company’s common stock at $0.53 a share to the research organization. On September 24, 2020, the Company issued 46,896 shares of common stock for the conversion of $18,000 convertible notes payable and $2,000 of related accrued interest. On September 25, 2020, the company issued 500,000 shares of the company’s common stock at $0.50 a share, which was a discount to the trading price of $0.80 a share, to a consultant for investor relation services. The discount was expensed at issuance and the rest of the expense will be amortized over the life of the agreement. On October 8, 2020, the company issued 350,000 shares of the company’s common stock at $0.48 a share, to a consultant for business development services. On October 13, 2020, the Company issued 64,421 shares of common stock for the conversion of $18,000 convertible notes payable and $2,000 of related accrued interest. On October 23, 2020, the Company issued 40,731 shares of common stock for the conversion of $10,000 convertible notes payable. On November 16, 2020, the Company issued 90,000 shares of the Company’s common stock at $0.17 a share for conversion of $15,000 convertible note payable. On November 23, 2020, the Company issued 122,051 shares of the Company’s common stock at $0.18 a share for conversion of $20,000 convertible note and $1,714 of related accrued interest. On December 8, 2020, the Company issued 135,695 shares of the Company’s common stock at $0.15 a share to the research organization. On December 11, 2020, the Company issued 1,000,000 shares of the Company’s common stock at $0.27 a share to a consulting company for services. On December 17, 2020, the Company executed an intellectual property rights purchase and transfer agreement whereby this agreement grants certain IP to the Company. In connection with the execution of this agreement, the Company issued 1,000,000 shares of the Company’s common stock at $0.27 a share to the research organization. On December 18, 2020, the Company issued 70,973 shares of the Company’s common stock at $0.14 a share for the conversion of $10,000 note payable with $318 of related accrued interest. Stock Options On May 4, 2020, the Company granted options to purchase 6,050,000 shares of common stock at a price of $0.57 per share to certain directors and employees of the Company (including our named executive officers) and are exercisable for ten years. One quarter of these options vest on the grant day, and the remainder of the options vest equally over thirty-six (36) months starting January 1, 2020. These options were valued at $3,152,050 using a Black-Scholes Options Pricing Model. On May 18, 2020, the Company granted options to purchase 75,000 shares of common stock at a price of $0.51 per share to a consultant and are exercisable for ten years. One quarter of these options vest on the grant day, and the remainder of the options vest equally over twelve (12) months. These options were valued at $34,260 using a Black-Scholes Options Pricing Model. On September 14, 2020 and December 24, 2020, the Company granted options to purchase 250,000 shares of common stock, respectively, at a price of $0.84 and $0.20 per share, respectively, to a consultant and are exercisable for ten years. One quarter of these options vest on the grant day, and the remainder of the options vest equally over twelve (12) months. These options were valued at $180,950 using a Black-Scholes Options Pricing Model. On September 23, 2020, the Company granted options to purchase 200,000 shares of common stock at a price of $0.80 per share to a consultant, who is a related party, and are exercisable for ten years. One quarter of these options vest on the grant day, and the remainder of the options vest equally over twenty-four (24) months. These options were valued at $109,060 using a Black-Scholes Options Pricing Model. On December 28, 2020, the Company granted options to purchase 200,000 shares of common stock at a price of $0.18 per share to a consultant and are exercisable for ten years. One quarter of these options vest on the grant day, and the remainder of the options vest equally over twelve (12) months. These options were valued at $26,720 using a Black-Scholes Options Pricing Model. For the years ended December 31, 2020 and 2019, the Company recorded $1,263,425 and $5,878, respectively, as stock-based compensation which is included in the general and administrative expenses in the consolidated statement of operations and $459,175 and $0 respectively, as research and development expense. The remaining expense outstanding through December 31, 2022 is $1,780,440. The fair value of the options is estimated using a Black-Scholes Options Pricing Model with the following assumptions: Market value of common stock on issuance date $0.18 - 0.84 Exercise price $0.18 - 2.00 Expected volatility 86% - 138% Expected term (in years) 5.5 – 6.5 Risk-free interest rate 0.64% – 1.73 Expected dividend yields — On August 14, 2019, the Board authorized the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) in order to facilitate the grant of cash and equity incentives to directors, employees (including our named executive officers) and consultants of our company and certain of its affiliates and to enable our company and certain of its affiliates to obtain and retain services of these individuals, which is essential to our long-term success. Our 2019 Plan allows for the grant of a variety of equity vehicles to provide flexibility in implementing equity awards, including incentive stock options, non-qualified stock options, restricted stock grants, unrestricted stock grants and restricted stock units. A total of 7,500,000 shares of common stock were authorized under the 2019 Plan, which was amended to 11,500,000 shares of common stock, for which as of December 31, 2020 a total of 6,050,000 are outstanding. The following is a summary of outstanding and exercisable options: Number of Options Weighted Avg Exercise Price Weighted Avg Remaining Years Outstanding as of December 31, 2019 100,000 $ 2 9.51 Granted 7,025,000 0.56 — Exercised — — — Forfeited — — — Expired — — — Outstanding as of December 31, 2020 7,125,000 $ 0.58 9.9 Outstanding as of December 31, 2020, vested 3,478,906 $ 0.61 9.13 Warrants In December 2019, the Company entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell the investor a $100,000 convertible note bearing interest at 8% per annum. The Company also sold warrants to the investors to purchase up to an aggregate of 100,000 shares of common stock, with an exercise term of three (3) years, at a per share purchase price of one hundred twenty five percent (125%) of the voluntary or involuntary conversion price of the Company’s 8% convertible note. The warrants were deemed as a derivative liability and was recorded as a debt discount at date of issuance. See Note 10. In January and February 2020, the Company entered into a Securities Purchase Agreement with investors pursuant to which the Company agreed to sell the investors a $100,000 and $50,000 convertible note bearing interest at 8% per annum, respectively. The Company also sold warrants to the investors to purchase up to an aggregate of 100,000 and 50,000 shares of common stock, respectively, with an exercise term of three (3) years, at a per share purchase price of one hundred twenty five percent (125%) of the voluntary or involuntary conversion price of the Company’s 8% convertible note. The warrants were deemed as a derivative liability and was recorded as a debt discount at date of issuance. See Note 10. On June 8, 2020, the Company entered into a Securities Purchase Agreement, dated as of June 2, 2020 (the “Purchase Agreement”) with an accredited investor pursuant to which the investor purchased a 12% unsecured convertible promissory note (the “12% Note”) from the Company. In connection with the Purchase Agreement and the 12% Note, the Company issued a common stock purchase warrant to purchase 36,666 shares of the Company’s common stock at $0.75 per share which may be exercised by cashless exercise, exercisable for a period of three years. The warrants were deemed as a derivative liability and was recorded as a debt discount at date of issuance. See Note 10. On June 23, 2020, the Company entered into a Securities Purchase Agreement, dated as of June 19, 2020 with an accredited investor pursuant to which the Investor purchased a 12% convertible promissory note from the Company. In connection with the securities purchase agreement and the note, the Company issued two common stock purchase warrants each to purchase 115,385 shares of the Company’s common stock at $1.30 per share which may be exercised by cashless exercise, exercisable for a period of five years. One of the warrants is to be issued only in the case of default on the note. During the year ended December 31, 2020, the anti-dilution clause was triggered and the exercise price was reset to $0.15 resulting in the number of warrants to be increased to 1,002,677. The warrants were deemed as a derivative liability and was recorded as a debt discount at date of issuance. See Note 10. The following is a summary of outstanding and exercisable warrants: Number of Shares Weighted Average Exercise Price Balance at December 31, 2019 100,000 $ 3.26 Granted 1,189,343 0.44 Forfeited — — Exercised — — Expired — — Balance at December 31, 2020 1,289,343 $ 0.18 At December 31, 2020, 1,289,343 warrants for common stock were exercisable and the intrinsic value of these warrants was $0. The weighted average remaining contractual life for warrants outstanding was 3.93 years.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 16 – RELATED PARTY TRANSACTIONS The Company’s Chief Executive Officer (“CEO”) shares the use of the leased office space for personal living quarters. The CEO reimburses the Company for 50% of the monthly rent, or $2,800 per month. As of December 31, 2020, the Company owes the CEO $130,00 for accrued compensation and $55,258 for expenses the CEO incurred on behalf of the Company. See Notes 8, 11 and 15 for additional related party transactions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 17 – INCOME TAXES We file income tax returns in the United States federal jurisdiction and in various state and local jurisdictions. In the normal course of business, we are subject to examination by taxing authorities. The tax years ending 2017 through 2020 remain subject to examination for federal tax purposes and remain subject to examination in significant state tax jurisdictions. As of December 31, 2020, and 2019, the Company had federal and state net operating loss carry forwards of $7,070,000 and $4,220,000, respectively, of which $.8 million of the 2020 amount will expire in 2033 through 2037, and $6.2 million will not expire. The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2020 and 2019 is as follows: For the Years ended December 31, 2020 2019 % % Statutory federal tax rate 21.0 21.0 State taxes, net of federal benefit 6.4 4.7 Valuation allowance (28.2 ) (20.0 ) Permanent items 1.4 (5.2 ) Other, net (0.8 ) (0.5 ) Provision for income taxes (0.2 ) — The change in the Company's net increase in the valuation allowance was caused by the change in estimation of NOL utilization. Deferred income taxes reflect the net tax effects of: (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes; and (b) operating loss and tax credit carry-forwards. We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. Significant components of deferred tax assets as December 31, 2020 and 2019 were as follows: For the Years ended December 31, 2020 2019 Deferred Tax Assets: Federal net operating loss carryforwards $ 1,457,706 $ 892,000 Stock based compensation 476,938 — Non-cash interest 68,405 39,954 Non-cash accrued compensation 877.976 794,880 Fixed assets 3,616 — State taxes 408,828 316,238 Net deferred tax assets before valuation allowance 3,293,468 2,043,072 Valuation Allowance (3,293,468 ) (2,043,072 ) Net Deferred Tax Assets $ — $ — Utilization of the net operating losses (NOL) carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code (IRC) of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders. At the time of closing the books, the Company had not yet completed a study to determine the extent of the limitation.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 18 – SUBSEQUENT EVENTS In January 2021, the Company issued 313,972 shares of common stock at the price of $0.19 per share for the purchase of intellectual property based on a five year installment sale. This compensation is included in research and development on the consolidated statement of operations. The issuance was an error and was intended, as per agreement to be 200,000 shares at the floor price of $.30 per share. The Company and the recipient have discussed the cancellation of 113,972 shares which will occur in the second quarter of 2021. See Note 12. In January 2021, the Company repaid $20,000 to its Chief Executive Officer in exchange for the discharge of a portion of his accrued expenses. On January 4, 2021, the Company issued 109,098 shares of common stock for the conversion of $10,000 convertible notes payable and $272 of related accrued interest. On January 12, 2021, the Company issued 175,000 shares of common stock at the price of $0.10 per share in exchange for a settlement of accrued expenses. On January 13, 2021, the Company issued 117,609 shares of common stock for the conversion of $10,000 convertible notes payable and $97 of related accrued interest. On January 14, 2021, the Company sold 258,559 shares of common stock at the purchase price of $0.11 per share for a total purchase price of $28,571. On January 15, 2021, the company issued 29,167 shares of the company’s common stock at $0.22 a share to a consultant for business development services. On January 27, 2021, the Company sold 388,583 shares of common stock at the purchase price of $0.13 per share for a total purchase price of $51,410. On February 1, 2021, the Company issued 288,036 shares of common stock for the conversion of $25,000 convertible notes payable and $162 of related accrued interest. On February 2, 2021, the Company issued 229,638 shares of common stock for the conversion of $20,000 convertible notes payable. On February 10, 2021, the Company issued 243,688 shares of common stock for the conversion of $20,000 convertible notes payable and $4,200 of related accrued interest. On February 10, 2021, the Company sold 697,714 shares of common stock at the purchase price of $0.17 per share for a total purchase price of $121,577. On February 10, 2021, the Company entered into a letter agreement with Lyons Capital, pursuant to which the Company agreed to issue and sell 3,500,000 shares of the Company’s common stock, par value $0.0001 per share, and two warrants to purchase an aggregate of 3,500,000 additional shares of Common Stock, the terms of such warrants are further discussed below, for an aggregate purchase price of $1,207,500. The first warrant grants Lyons Capital the right to purchase up to 1,750,000 shares of common stock at an exercise price of $0.22 per share. The second warrant grants Lyons Capital the right to purchase up to an additional 1,750,000 shares of common stock at an exercise price of $0.27 per share. The warrants are exercisable immediately, will expire five years from the date of issuance, and contain customary provisions allowing for adjustment to the exercise price and number of shares of common stock issuable upon exercise in the event of any stock dividend, recapitalization, reorganization, reclassification, or similar transaction. subject to limited exceptions, Lyons Capital may not exercise any portion of the warrants if Lyons Capital, together with any of its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. On February 22, 2021, the Company sold 715,893 shares of common stock at the purchase price of $0.16 per share for a total purchase price of $115,617. On February 26, 2021, the Company sold 1,050,045 shares of common stock at the purchase price of $0.09 per share for a total purchase price of $90,146. On March 2, 2021, the Company issued 520,000 shares of common stock at the price of $0.10 per share in exchange for a settlement of accrued expenses. On March 4, 2021, the company issued 320,833 shares of the company’s common stock at $0.22 a share to a consultant for business development services. On March 12, 2021, the Company granted options to purchase 7,350,000 shares of common stock at a price of $0.13 per share to certain directors and employees of the Company (including our named executive officers) and are exercisable for ten years. One quarter of these options vest on the grant day, and the remainder of the options vest equally over thirty-six (36) months starting March 12, 2021. These options were valued at $732,795 using a Black-Scholes Options Pricing Model. In March 2021, the Company granted options to purchase 200,000 shares of common stock at a price of $0.13 per share to a certain member of the Company’s corporate advisory board, as governed under agreement. One quarter of these options vested on the grant day, and the remainder of the options vest equally over twenty four (24) months thereafter. These options were valued at $19,940 using a Black-Scholes Options Pricing Model. In March 2021, the Company entered into a new lease agreement with Thermo Fisher Scientific to acquire another piece of equipment with 36 monthly payments of $699 (including tax), payable through March 2024, with an effective interest rate of 13.4% per annum. The outstanding balance of this capital lease as of March 30, 2021 was $24,637, with a carrying value of $24,637. In March 2021, the Company issued 692,308 restricted shares or common stock at a price of $0.13 per share to its Chief Executive Officer in exchange for the discharge of a portion of his accrued but unpaid salary.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP.
Principles of Consolidation	Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Kannalife. All significant consolidated transactions and balances have been eliminated in consolidation.
Noncontrolling Interests	Noncontrolling Interests The Company accounts for its less than 100% interests in Kannalife in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of Kannalife’s net loss attributable to noncontrolling interests in the consolidated statement of operations. On August 30, 2019, the Company issued 171,000 shares of common stock at a price of $0.07 per share to acquire the remaining non-controlling interest in Kannalife Sciences, Inc., bringing our ownership interest from 99.7% to 100%.
Significant risks and uncertainties	Significant Risks and Uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. In December 2019, a novel strain of coronavirus, commonly known as COVID-19, surfaced. The spread of COVID-19 around the world in 2020 has caused significant volatility in U.S. and international markets. The Company’s operations as of December 31, 2020 have not been significantly affected, but may be affected in the future, by the ongoing outbreak of COVID-19 which was declared a pandemic by the World Health Organization. The ultimate disruption which may be caused by the outbreak is uncertain; however, it may result in a material adverse impact on the Company’s financial position, operations and cash flows. Possible areas that may be affected include, but are not limited to, disruption to the Company’s labor workforce, unavailability of products and supplies used in operations, and the decline in value of assets held by the Company.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Company’s stock, stock-based compensation, valuation of derivative liabilities and valuation allowance relating to the Company’s deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made.
Cash and Cash Equivalents	Cash and Cash Equivalents Our cash and cash equivalents include short-term, highly liquid investments with original maturities of three months or less when purchased. At times throughout the year, the Company may maintain bank balances that could exceed Federal Deposit Insurance Corporation insured limits. The Company maintains its cash deposit accounts with high credit quality financial institutions, and therefore believes that its loss exposure is minimal.
Accounts Receivable	Accounts Receivable Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers’ accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. As of December 31, 2020 and 2019, the Company had no allowance for doubtful account.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense when incurred, while renewals and betterments that materially extend the life of an asset are capitalized. When assets are sold, retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheets and any resulting gain or loss is reflected in the statements of operations and members’ deficit in the period realized. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are as follows: Furniture and equipment 5 years
Joint Venture	Joint Venture On June 18, 2019, the Company, along with MJNA, which is a significant shareholder, and AXIM Biotechnologies, Inc., whose president is affiliated with a shareholder, entered into a joint venture agreement with an industrial hemp production farm for the supply of certain industrial hemp CBD crops. The purpose of the joint venture is to share in the harvested yield of the hemp production which the Company hopes to result in a steady supply of industrial hemp CBD for research and development purposes. The Company accounts for its participation in the joint venture under the equity method of accounting. The Company has no control or influence over the joint venture and for the year ending December 31, 2019 the Company recorded a loss in investment in the amount of $27,490. As of December 31,2020, the Company is no longer part of this joint venture.
Revenue Recognition	Revenue Recognition The FASB issued Accounting Standards Update (“ASU”) No. 2014-09, codified as ASC 606: Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. Revenue consists of research funding from the Company’s National Institute of Health (“NIH”) Grant. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met. For the year ended December 31, 2020, the company recognized $0 in grant revenue.
Equity Investments	Equity Investments Effective January 1, 2018, with the adoption of ASU 2016-01, our accounting treatment for equity investments differs for those with and without readily determinable fair values. Equity investments with readily determinable fair values are recorded at fair value with changes in fair value recorded in “Unrealized Gain/Loss On Investments.” For equity investments without readily determinable fair values we have elected the “measurement alternative,” and therefore carry these investments at cost, less impairment (if any), plus or minus changes in observable prices. On a quarterly basis, we review our equity investments without readily determinable fair values for impairment. We consider a number of qualitative factors such as whether there is a significant deterioration in earnings performance, credit rating, asset quality, or business prospects of the investee in determining if impairment exists. If the investment is considered impaired, an impairment loss equal to the amount by which the carrying value exceeds its fair value is recorded through a charge to earnings. The impairment loss may be reversed in a subsequent period if there are observable transactions for the identical or similar investment of the same issuer at a higher amount than the carrying amount that was established when the impairment was recognized. Impairment as well as upward or downward adjustments resulting from observable price changes in orderly transactions for identical or similar investments are included in “Income - other.” Realized gains or losses resulting from the sale of equity investments are calculated using the specific identification method and are included in “Net gains and losses recognized on marketable security".
Income Taxes	Income Taxes The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes
Preferred Stock	Preferred Stock The Company applies the guidance enumerated in FASB ASC Topic 480, Distinguishing Liabilities from Equity
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC Topic 815, Derivatives and Hedging Activities Applicable U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments) as follows. The Company records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
Stock Based Compensation	Stock Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provision of FASB ASC 718, Compensation – Stock Compensation The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505, Equity–based Payments to Non-Employees .
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 17,174,152 and 4,029,433 for the years ended December 31, 2020 and 2019, respectively.
Research and Development	Research and Development In accordance with FASB ASC 730, Research and Development
Recently Issued Authoritative Guidance	Recently Issued Authoritative Guidance In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation is not needed until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s consolidated financial statements.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis	The following table presents liabilities that are measured and recognized at fair value as of December 31, 2020 and 2019, on a recurring basis: December 31, 2020 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities — — 316,189 $ 316,189 December 31, 2019 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities — — 183,451 $ 183,451

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	Accounts payable and accrued expenses at December 31, 2020 and 2019 consisted of the following: December 31, 2020 December 31, 2019 Accounts payable and accrued expenses $ 538,527 $ 309,231 Accrued interest 182,781 79,964 Totals $ 721,308 $ 389,195

Payroll and Related Liabiliti_2

Payroll and Related Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Schedule of Payroll and Related Liabilities	Payroll and related liabilities at December 31, 2020 and 2019 consisted of the following: December 31, 2020 December 31, 2019 Payroll $ 149,704 $ — Payroll taxes 229,537 243,208 Totals $ 379,241 $ 243,208

Loan Payable (Tables)

Loan Payable (Tables)	12 Months Ended
	Dec. 31, 2020
Loan Payable Tables Abstract
Schedule of Loans Payable	December 31, 2020 December 31, 2019 Loan payable at 8%, matures 12/31/2020 * {a} $ 850,000 $ 620,000 Loan payable at 0%, matures 6/11/2021 * 100,000 — Total 950,000 620,000 {a} – The maturity date of the loan has been extended to December 31, 2021. * - unsecured note

Convertible Notes Payable - R_2

Convertible Notes Payable - Related Party (Tables)	12 Months Ended
	Dec. 31, 2020
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract]
Schedule of future debt payments	The following is a schedule by year of future debt payments at December 31, 2020. Year Ending December 31, Loan payable Loan payable - related party Convertible notes payable Convertible notes payable - related party Total 2021 $ 950,000 $ 42,092 $ 40,400 $ 100,000 $ 1,496,092 2022 — — — $ 50,000 $ 50,000 2023 — — — — — 2024 — — — — — 2025 — — — — — Thereafter — — $ 376,373 — $ 376,373 Total $ 950,000 $ 42,092 $ 780,373 $ 150,000 $ 1,922,465

Patent Purchase Liability (Tabl

Patent Purchase Liability (Tables)	12 Months Ended
	Dec. 31, 2020
Notes To Financial Statements Abstract
Schedule of patent purchase	For the year ended December 31, 2020, the Company expensed $587,962 related to the patent purchase which was included in research and development expenses on the accompanying consolidated statements of operations. Maturity of Patent Purchase Liability 2021 $ 75,000 2022 75,000 2023 75,000 2024 75,000 2025 75,000 Total undiscounted payments $ 375,000 Less: imputed interest 57,038 Present value of patent purchase liabilities $ 317,962

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Schedule of Derivative Liabilities	Based on the various convertible notes described in Note 10 and 11, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows for the year ended December 31, 2020: Derivative Liability - Convertible Notes Derivative Liability - Warrants Total Balance as of December 31, 2019 $ 61,430 $ 122,021 $ 183,451 Additions during the period 597,841 353,779 951,620 Change in fair value (439,744 ) (312,751 ) (752,495 ) Change due to exercise / redemptions (66,387 ) — (66,387 ) Balance as of December 31, 2020 $ 153,140 $ 163,049 $ 316,189
Warrants
Schedule of share-based payment award, stock options, valuation assumptions	The fair value of the derivative liability – warrants is estimated using a Monte Carlo pricing model with the following assumptions: Market value of common stock $0.58 - 1.80 Expected volatility 0.98% - 160.1% Expected term (in years) 1.98 - 5.00 Risk-free interest rate 0.18% - 1.57%
Convertible Notes
Schedule of share-based payment award, stock options, valuation assumptions	The fair value of the derivative liability – convertible notes is estimated using a Monte Carlo pricing model with the following assumptions: Market value of common stock $0.14 – 0.58 Expected volatility 87.9% - 112.7% Expected term (in years) 0.19 – 2.00 Risk-free interest rate 0.06% - 1.55%

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2020
Schedule of outstanding and exercisable options	The following is a summary of outstanding and exercisable options: Number of Options Weighted Avg Exercise Price Weighted Avg Remaining Years Outstanding as of December 31, 2019 100,000 $ 2 9.51 Granted 7,025,000 0.56 — Exercised — — — Forfeited — — — Expired — — — Outstanding as of December 31, 2020, 7,125,000 $ 0.58 9.9 Outstanding as of December 31, 2020, vested 3,478,906 $ 0.61 9.13
Schedule of outstanding and exercisable warrants	The following is a summary of outstanding and exercisable warrants: Number of Shares Weighted Average Exercise Price Balance at December 31, 2019 100,000 $ 3.26 Granted 1,189,343 0.44 Forfeited — — Exercised — — Expired — — Balance at December 31, 2020 1,289,343 $ 0.18
Option [Member]
Schedule of share-based payment award, stock options, valuation assumptions	The fair value of the options is estimated using a Black-Scholes Options Pricing Model with the following assumptions: Market value of common stock on issuance date $0.18 - 0.84 Exercise price $0.18 - 2.00 Expected volatility 86% - 138% Expected term (in years) 5.5 – 6.5 Risk-free interest rate 0.64% – 1.73 Expected dividend yields —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2020 and 2019 is as follows: For the Years ended December 31, 2020 2019 % % Statutory federal tax rate 21.0 21.0 State taxes, net of federal benefit 6.4 4.7 Valuation allowance (28.2 ) (20.0 ) Permanent items 1.4 (5.2 ) Other, net (0.8 ) (0.5 ) Provision for income taxes (0.2 ) —
Schedule of Deferred Tax Assets and Liabilities	Significant components of deferred tax assets as December 31, 2020 and 2019 were as follows: For the Years ended December 31, 2020 2019 Deferred Tax Assets: Federal net operating loss carryforwards $ 1,457,706 $ 892,000 Stock based compensation 476,938 — Non-cash interest 68,405 39,954 Non-cash accrued compensation 877.976 794,880 Fixed assets 3,616 — State taxes 408,828 316,238 Net deferred tax assets before valuation allowance 3,293,468 2,043,072 Valuation Allowance (3,293,468 ) (2,043,072 ) Net Deferred Tax Assets $ — $ —

Organization and Nature of Op_2

Organization and Nature of Operations (Details Narrative)	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of Incorporation	Mar. 25, 2013

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 18, 2020	Nov. 23, 2020	Nov. 16, 2020	Sep. 26, 2019
Stock Issued During Period, Shares, Acquisitions	171,000
Share Price	$ .07			$ 0.14	$ 0.18	$ 0.17	$ 0.10
Allowance for doubtful account		$ 0	$ 0
Loss in investment			27,490
Grant revenue		$ 0	$ 126,027
Weighted average number of common stock, anti-dilutive		17,174,152	4,029,433
Research and Development		$ 1,095,405	$ 554,701
Furniture and equipment Useful Life		5 years
Minimum [Member]
Ownership, percentage	99.70%
Maximum [Member]
Ownership, percentage	100.00%

Going Concern and Management'_2

Going Concern and Management's Liquidity Plans (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss from operations	$ (4,473,728)	$ (2,329,117)
Net cash used in operating activities	(944,198)	(1,894,085)
Accumulated deficit	$ (13,033,363)	$ (8,496,088)

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value, liabilities Measured on Recurring Basis (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Derivative liabilities	$ 316,189	$ 183,451
Level 1
Derivative liabilities	0	0
Level 2
Derivative liabilities	0	0
Level 3
Derivative liabilities	316,189	183,451
Total Carrying Value
Derivative liabilities	$ 316,189	$ 183,451

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 538,527	$ 309,231
Accrued interest	182,781	79,964
Totals	$ 721,308	$ 389,195

Payroll and Related Liabiliti_3

Payroll and Related Liabilities - Schedule Of Accrued Payroll And Payroll Taxes (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Accrued Payroll And Payroll Taxes - Schedule Of Accrued Payroll And Payroll Taxes
Payroll	$ 149,704	$ 0
Payroll taxes	229,537	243,208
Totals	$ 379,241	$ 243,208

Payroll and Related Liabiliti_4

Payroll and Related Liabilities (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Payroll taxes	$ 229,537	$ 243,208
Chief Executive Officer
Payroll taxes	130,000
Director [Member]
Payroll taxes	$ 12,500

Loan Payable - Loans payable (D

Loan Payable - Loans payable (Details) - USD ($)		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Total		$ 950,000	$ 620,000
Debt Instrument, interest rate		0.50%
Debt instrument, maturity date		Mar. 31, 2021
Loan payable One [Member]
Total	[1],[2]	$ 850,000	$ 620,000
Debt Instrument, interest rate		8.00%	8.00%
Debt instrument, maturity date		Dec. 31, 2020	Jun. 11, 2021
Loan payable two [Member]
Total	[2]	$ 100,000	$ 0
Debt Instrument, interest rate		0.00%	0.00%
Debt instrument, maturity date		Jun. 11, 2021	Jun. 11, 2021
[1]	The maturity date of the loan has been extended to December 31, 2021.
[2]	unsecured note

Loan Payable (Details Narrative

Loan Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Interest expense	$ 54,444	$ 48,921
Accrued interest	$ 127,825	$ 73,381
Maturity date	Mar. 31, 2021

Loan Payable - Related Party (D

Loan Payable - Related Party (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Maturity date	Mar. 31, 2021
Interest rate	0.50%
Advanced from related party	$ 55,258	$ 25,349
Related Party Promissory Note
Note payable, related party	25,822
Accrued interest, related party note	226	$ 226
Advanced from related party	16,270
Working capital	$ 42,092

Capital Lease Obligations (Deta

Capital Lease Obligations (Details Narrative) - USD ($)	1 Months Ended
	Sep. 30, 2019	Dec. 31, 2020
Debt Disclosure [Abstract]
Effective interest rate		12.00%
Frequency period	P48M
Monthly payment	$ 941
Capital Lease Obligations		$ 27,764
Equipment with carrying value		$ 46,131

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	Jun. 08, 2020	Mar. 12, 2020	Jun. 23, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 18, 2020	Nov. 23, 2020	Oct. 13, 2020	Sep. 24, 2020	Sep. 26, 2019	Jul. 24, 2015
Convertible debt								$ 376,373	$ 376,373
Common stock issued						74,225,141		77,670,908	77,670,908	74,225,141
Accrued interest											$ 318	$ 1,714	$ 2,000	$ 2,000	$ 26,373
Interest rate									0.50%
Amortization of debt discount									$ 376,661	$ 2,466
Periodic payment							$ 941
Securities Purchase Agreement [Member]
Number of warrants sold	36,666		115,385	50,000	100,000	100,000			1,002,677
Proceeds from sale of warrants				$ 50,000	$ 100,000	$ 100,000
Interest rate	12.00%		12.00%	8.00%	8.00%	8.00%
Convertible Debt
Principal amount																$ 500,000
Convertible debt																$ 500,000
Maturity date																Feb. 16, 2030
Interest rate																3.00%
Convertible price per share																$ 0.10
Common stock issued															1,500,000
Value of notes converted															$ 123,627
Accrued interest						$ 2,797		$ 39,993	$ 39,993	2,797					$ 26,373
Interest expense									349,889	16,739
Amortization of debt discount									306,662	$ 2,466
8% Notes
Principal amount		$ 105,000
Convertible debt								$ 99,000	$ 99,000
Maturity date		Mar. 12, 2021
Interest rate		8.00%
Debt discount		$ 5,000
Purchase price		$ 100,000
Debt conversion, description		The Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of the lesser of (i) $0.75 or (ii) 68% multiplied by the average of the two lowest trading closing prices of the Company’s common stock on the fifteen days before the issue date of this note or (ii) 68% multiplied by the average of the two lowest trading closing prices of the Company’s common stock on the fifteen days prior to conversion.
Common stock issued								570,767	570,767
Value of notes converted								$ 111,000	$ 111,000
Accrued interest								$ 6,032	$ 6,032
12% Note
Principal amount	$ 165,000
Interest rate	12.00%
Debt discount	$ 9,000
Purchase price	156,000
Repayment of related party debt	$ 52,000
Debt conversion, description	All principal amounts and the interest thereon are convertible into shares of the Company’s common stock at the option of the Investor, after six (6) months from the date of the 12% Note. All closings occurred following the satisfaction of customary closing conditions. The 12% Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of the lesser of (i) 68% multiplied by the lowest Trading Price (representing a discount rate of 32%) during the previous fifteen (15) trading day period ending on the latest complete trading day prior to the date of the 12% Note or (ii) the Variable Conversion Price.
Warrants per share value	$ 0.75
Transaction fees	$ 3,100
Warrants issued	36,666
12% convertible promissory note
Principal amount			$ 150,000
Maturity date			Jun. 19, 2021
Interest rate			12.00%
Debt discount			$ 20,750
Warrants per share value			$ 1.30					$ 0.15	$ 0.15
Number of warrants sold								1,002,677
Warrants issued			115,385
Periodic payment			$ 25,000

Convertible Notes Payable - R_3

Convertible Notes Payable - Related Party (Details)	Dec. 31, 2020USD ($)
2021	$ 1,496,092
2022	50,000
2023	0
2024	0
2025	0
Thereafter	376,373
Total	1,922,465
Loans Payable [Member]
2021	950,000
2022	0
2023	0
2024	0
2025	0
Thereafter	0
Total	950,000
Loan payable - related party [Member]
2021	42,092
2022	0
2023	0
2024	0
2025	0
Thereafter	0
Total	42,092
Convertible notes payable [Member]
2021	404,000
2022	0
2023	0
2024	0
2025	0
Thereafter	376,373
Total	780,373
Convertible Notes Payable Related Party [Member]
2021	100,000
2022	50,000
2023	0
2024	0
2025	0
Thereafter	0
Total	$ 150,000

Convertible Notes Payable - R_4

Convertible Notes Payable - Related Party (Details Narrative) - USD ($)	Jun. 08, 2020	Jun. 23, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 18, 2020	Nov. 23, 2020	Oct. 13, 2020	Sep. 24, 2020	Sep. 26, 2019
Amortization of debt discount						$ 376,661	$ 2,466
Accrued interest								$ 318	$ 1,714	$ 2,000	$ 2,000	$ 26,373
Convertible Notes Payable Related Party [Member]
Interest expense						81,178	0
Amortization of debt discount						70,000	0
Accrued interest					$ 0	$ 11,178	$ 0
Securities Purchase Agreement [Member]
Number of warrants sold	36,666	115,385	50,000	100,000	100,000	1,002,677
Proceeds from sale of warrants			$ 50,000	$ 100,000	$ 100,000
Securities Purchase Agreement [Member] | Kettner Investments
Number of warrants sold				100,000
Proceeds from sale of warrants				$ 100,000
Securities Purchase Agreement [Member] | Chief Executive Officer
Number of warrants sold			50,000
Proceeds from sale of warrants			$ 50,000

Patent Purchase Liability - Mat

Patent Purchase Liability - Maturity of Patent Purchase Liability (Details)	Dec. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 75,000
2022	75,000
2023	75,000
2024	75,000
2025	75,000
Total undiscounted payments	375,000
Less: imputed interest	57,038
Present value of patent purchase liabilities	$ 317,962

Patent Purchase Liability (Deta

Patent Purchase Liability (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 17, 2020	Dec. 31, 2020	Dec. 18, 2020	Nov. 23, 2020	Nov. 16, 2020	Sep. 26, 2019	Aug. 30, 2019
Shares price			$ 0.14	$ 0.18	$ 0.17	$ 0.10	$ .07
IP Purchase Agreement
Business acquisition, consideration	$ 570,000
Discount rate	8.00%
Acquisition cost		$ 587,962
IP Purchase Agreement | Restricted Common Stock
Business acquisition, shares issued	1,000,000
Business acquisition, shares issued, value	$ 270,000
Shares price	$ 0.27
IP Purchase Agreement | Common Stock
Business acquisition, shares issued, value	$ 300,000
IP Purchase Agreement | Common Stock | Minimum [Member]
Shares price	$ 0.30
IP Purchase Agreement | Common Stock | Maximum [Member]
Shares price	$ 0.60

Derivative Liabilities - Schedu

Derivative Liabilities - Schedule of Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance at beginning	$ 183,451
Additions during the period	951,620
Change in fair value	(752,495)	$ 4,367
Change due to exercise / redemptions	(66,387)
Balance at end	316,189	183,451
Convertible Notes
Balance at beginning	61,430
Additions during the period	597,841
Change in fair value	(439,744)
Change due to exercise / redemptions	(66,387)
Balance at end	153,140	61,430
Warrants
Balance at beginning	122,021
Additions during the period	353,779
Change in fair value	(312,751)
Change due to exercise / redemptions	0
Balance at end	$ 163,049	$ 122,021

Derivative Liabilities - Assump

Derivative Liabilities - Assumptions - Convertible notes (Details) - Convertible Notes	12 Months Ended
	Dec. 31, 2020$ / shares
Minimum [Member]
Market value of common stock on issuance date	$ 0.14
Expected volatility	87.90%
Expected term (in years)	2 months 8 days
Risk-free interest rate	0.06%
Maximum [Member]
Market value of common stock on issuance date	$ 0.58
Expected volatility	112.70%
Expected term (in years)	2 years
Risk-free interest rate	1.55%

Derivative Liabilities - Assu_2

Derivative Liabilities - Assumptions - Warrants (Details) - Warrants	12 Months Ended
	Dec. 31, 2020$ / shares
Minimum [Member]
Market value of common stock on issuance date	$ 0.58
Expected volatility	0.98%
Expected term (in years)	1 year 11 months 23 days
Risk-free interest rate	0.18%
Maximum [Member]
Market value of common stock on issuance date	$ 1.80
Expected volatility	160.10%
Expected term (in years)	5 years
Risk-free interest rate	1.57%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Jul. 02, 2018	Sep. 15, 2015	Apr. 01, 2014
Security Deposit	$ 17,121	$ 17,121
Office Space
Monthly Rent			$ 2,723	$ 359	$ 5,600
Security Deposit			$ 2,121	$ 183	$ 15,000

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of share-based payment award, stock options, valuation assumptions (Details) - Option [Member]	12 Months Ended
	Dec. 31, 2020$ / shares
Risk-free interest rate	1.73%
Expected dividend yields	0.00%
Minimum [Member]
Market value of common stock on issuance date	$ 0.18
Exercise price	$ 0.18
Expected volatility	86.00%
Expected term (in years)	5 years 6 months
Risk-free interest rate	0.64%
Maximum [Member]
Market value of common stock on issuance date	$ 0.84
Exercise price	$ 2
Expected volatility	138.00%
Expected term (in years)	6 years 6 months
Risk-free interest rate	1.73%

Stockholders' Deficit - Summary

Stockholders' Deficit - Summary of outstanding and exercisable Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Number of Options Outstanding, Beginning	100,000
Number of Options Granted	7,025,000
Number of Options Exercised	0
Number of Options Forfeited	0
Number of Options Expired	0
Number of Options Outstanding, Ending	7,125,000	100,000
Number of Options Exercisable	3,478,906
Weighted Average Exercise Price Outstanding, Beginning	$ 2
Weighted Average Exercise Price Granted	0.56
Weighted Average Exercise Price Exercised	0
Weighted Average Exercise Price Forfeited	0
Weighted Average Exercise Price Expired	0
Weighted Average Exercise Price Outstanding, Ending	0.58	$ 2
Weighted Average Exercise Price Exercisable	$ 0.61
Weighted Average Remaining Years Outstanding	9 years 10 months 25 days	9 years 6 months 3 days
Weighted Average Remaining Years, Exercisable	9 years 1 month 16 days

Stockholders' Deficit - Summa_2

Stockholders' Deficit - Summary of outstanding and exercisable warrants (Details) - Warrants	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Number of Warrants Outstanding, Beginning | shares	100,000
Number of Warrants Granted | shares	1,189,343
Number of Warrants Forfeited | shares	0
Number of Warrants Exercised | shares	0
Number of Warrants Expired | shares	0
Number of Warrants Outstanding, Ending | shares	1,289,343
Weighted Average Exercise Price Outstanding, Beginning | $ / shares	$ 3.26
Weighted Average Exercise Price Granted | $ / shares	0.44
Weighted Average Exercise Price Forfeited | $ / shares	0
Weighted Average Exercise Price Exercised | $ / shares	0
Weighted Average Exercise Price Expired | $ / shares	0
Weighted Average Exercise Price Outstanding, Ending | $ / shares	$ 0.18

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Dec. 11, 2020	Dec. 08, 2020	Oct. 13, 2020	Oct. 08, 2020	Sep. 14, 2020	Jun. 08, 2020	May 04, 2020	Dec. 28, 2020	Dec. 24, 2020	Dec. 18, 2020	Dec. 17, 2020	Nov. 23, 2020	Nov. 16, 2020	Oct. 23, 2020	Sep. 25, 2020	Sep. 24, 2020	Sep. 23, 2020	Sep. 18, 2020	Jun. 23, 2020	May 18, 2020	Apr. 28, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Sep. 26, 2019	Aug. 31, 2019	Aug. 30, 2019	Dec. 31, 2020	Dec. 31, 2019
Common Stock Description																												All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative, and therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders.
Common Stock, Par or Stated Value Per Share																								$ 0.0001				$ 0.0001	$ 0.0001
Common Stock, Shares Authorized																								200,000,000				200,000,000	200,000,000
Share Price										$ 0.14		$ 0.18	$ 0.17												$ 0.10		$ .07
Stock Issued During Period, Shares, Acquisitions																											171,000
Number of common stock converted			64,421							70,973		122,051	90,000	40,731		46,896									1,500,000
Value of notes converted			$ 18,000							$ 10,000		$ 20,000	$ 15,000	$ 10,000		$ 18,000									$ 123,627
Accrued interest			$ 2,000							$ 318		$ 1,714				$ 2,000									$ 26,373
Options granted, exercise price																												$ 0.56
Stock based compensation																												$ 1,722,600	$ 275,878
Unrecognized compensation expense																												$ 1,780,440
Common stock authorized under plan																								7,500,000				6,050,000	7,500,000
Interest rate																												0.50%
Warrant Exercisable																												1,289,343
Intrinsic value of warrants																												$ 0
Weighted average remaining contractual life of warrants outstanding																												3 years 11 months 4 days
Stock Option [Member]
Options granted					250,000		6,050,000	200,000	250,000								200,000			75,000
Options granted, exercise price					$ 0.84		$ 0.57	$ 0.18	$ 0.20								$ 0.80			$ 0.51
Vesting period					10 years		10 years	10 years	10 years								10 years			10 years
Value of option					$ 180,950		$ 3,152,050	$ 26,720	$ 180,950								$ 109,060			$ 34,260
Series B Preferred Stock [Member]
Preferred stock description																												Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series A Preferred Stock. Each share of the Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company’s board of directors and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share.
Board members
Stock Issued During Period, Shares, Issued for Services																										950,000
Share Price																										$ 0.10
Investor Relations Consultant
Stock Issued During Period, Shares, Issued for Services																										500,000
Share Price																										$ 0.10
Product Development Consultant
Stock Issued During Period, Shares, Issued for Services																										150,000
Share Price																										$ 0.10
Marketing Consultant
Stock Issued During Period, Shares, Issued for Services																										400,000
Share Price																										$ 0.10
Consultant
Stock Issued During Period, Shares, Issued for Services	1,000,000			350,000											500,000											700,000
Share Price	$ 0.27			$ 0.48											$ 0.50											$ 0.10
Research Organization
Share Price		$ 0.15									$ 0.27										$ 0.53
Stock Issued During Period, Shares, Acquisitions		135,695									1,000,000										25,000
Equity Purchase Agreement [Member] | Cross & Company [Member]
Purchase price																		$ 6,000,000
Securities Purchase Agreement [Member]
Share Price																			$ 1.30									$ 0.15
Number of warrants sold						36,666													115,385			50,000	100,000	100,000				1,002,677
Proceeds from sale of warrants																						$ 50,000	$ 100,000	$ 100,000
Interest rate						12.00%													12.00%			8.00%	8.00%	8.00%
Warrant term						3 years																3 years	3 years	3 years

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Chief Executive Officer	12 Months Ended
	Dec. 31, 2020USD ($)
Monthly rent	$ 2,800
Accrued compensation	13,000
Related party cost	$ 55,258

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Text Block [Abstract]
Statutory federal tax rate	21.00%	21.00%
State taxes, net of federal benefit	6.40%	4.70%
Valuation allowance	(28.20%)	(20.00%)
Permanent items	1.40%	(5.20%)
Other, net	(0.80%)	(0.50%)
Provision for income taxes	(0.20%)	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred Tax Assets:
Federal net operating loss carryforwards	$ 1,457,706	$ 892,000
Stock based compensation	476,938	0
Non-cash interest	68,405	39,954
Non-cash accrued compensation	877,976	794,880
Fixed assets	3,616	0
State taxes	408,828	316,238
Net deferred tax assets before valuation allowance	3,293,468	2,043,072
Valuation Allowance	(3,293,468)	(2,043,072)
Net Deferred Tax Assets	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating loss carry forwards	$ 7,070,000	$ 4,220,000
Income tax, description	Respectively, of which $.8 million of the 2020 amount will expire in 2033 through 2037, and $6.2 million will not expire.
Stockholders
Ownership, percentage	50.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jan. 15, 2021	Jan. 14, 2021	Jan. 13, 2021	Jan. 12, 2021	Jan. 04, 2021	Oct. 13, 2020	Feb. 27, 2021	Feb. 10, 2021	Feb. 02, 2021	Feb. 01, 2021	Jan. 31, 2021	Dec. 18, 2020	Nov. 23, 2020	Nov. 16, 2020	Oct. 23, 2020	Sep. 24, 2020	Sep. 26, 2019	Aug. 30, 2019	Mar. 12, 2021	Mar. 04, 2021	Mar. 02, 2021	Feb. 26, 2021	Feb. 22, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Shares issued for acquisition																		171,000
Shares price												$ 0.14	$ 0.18	$ 0.17			$ 0.10	$ .07
Debt conversion, converted instrument, shares issued						64,421						70,973	122,051	90,000	40,731	46,896	1,500,000
Debt conversion, converted instrument, amount						$ 18,000						$ 10,000	$ 20,000	$ 15,000	$ 10,000	$ 18,000	$ 123,627
Proceeds from related party debt																									$ 0	$ 97
Shares issued for services, value																									$ 844,708	$ 175,000
Options granted, exercise price																									$ 0.56
Interest rate																									0.50%
Subsequent Event [Member]
Shares issued for acquisition											313,972
Shares price											$ 0.19
Cancellation of shares											113,972
Debt conversion, converted instrument, shares issued			117,609	175,000	109,098			243,688	229,638	288,036											520,000
Debt conversion, converted instrument, amount			$ 10,000		$ 10,000			$ 20,000	$ 20,000	$ 25,000
Debt conversion, converted instrument, interest			$ 97		$ 272			$ 4,200		$ 162
Shares issued price per share	$ 0.22	$ 0.11		$ 0.10			$ 0.13	$ 0.17												$ 0.22	$ 0.10	$ 0.09	$ 0.16
Shares issued to related party		258,559					388,583	697,714														1,050,045	715,893
Proceeds from related party debt		$ 28,571					$ 51,410	$ 121,577														$ 90,146	$ 115,617
Shares issued for services, shares	29,167																			320,833
Options granted																			7,350,000					200,000
Options granted, exercise price																			$ 0.13					$ 0.13
Vesting period																			10 years
Value of option																			$ 732,795					$ 19,940
Subsequent Event [Member] | Letter Agreement
Shares issued price per share								$ 0.0001
Shares issued to related party								3,500,000
Proceeds from related party debt								$ 1,207,500
Warrant description								The first warrant grants Lyons Capital the right to purchase up to 1,750,000 shares of common stock at an exercise price of $0.22 per share. The second warrant grants Lyons Capital the right to purchase up to an additional 1,750,000 shares of common stock at an exercise price of $0.27 per share.
Subsequent Event [Member] | Lease Agreement
Rent expenses																								$ 699
Interest rate																								13.40%
Capital lease liabilities											$ 24,637
Carrying value of capital lease											24,637
Subsequent Event [Member] | Chief Executive Officer
Repayment of related party debt											$ 20,000
Shares issued price per share																								$ 0.13
Shares issued for services, shares																								692,308